JP2019506390A5 - - Google Patents

Download PDF

Info

Publication number
JP2019506390A5
JP2019506390A5 JP2018537799A JP2018537799A JP2019506390A5 JP 2019506390 A5 JP2019506390 A5 JP 2019506390A5 JP 2018537799 A JP2018537799 A JP 2018537799A JP 2018537799 A JP2018537799 A JP 2018537799A JP 2019506390 A5 JP2019506390 A5 JP 2019506390A5
Authority
JP
Japan
Prior art keywords
vaccine
hapten
class drug
fentanyl class
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018537799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506390A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/013865 external-priority patent/WO2017127390A1/en
Publication of JP2019506390A publication Critical patent/JP2019506390A/ja
Publication of JP2019506390A5 publication Critical patent/JP2019506390A5/ja
Pending legal-status Critical Current

Links

JP2018537799A 2016-01-21 2017-01-18 合成オピオイドワクチン Pending JP2019506390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281262P 2016-01-21 2016-01-21
US62/281,262 2016-01-21
PCT/US2017/013865 WO2017127390A1 (en) 2016-01-21 2017-01-18 Synthetic opioid vaccine

Publications (2)

Publication Number Publication Date
JP2019506390A JP2019506390A (ja) 2019-03-07
JP2019506390A5 true JP2019506390A5 (enExample) 2020-02-27

Family

ID=59362842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018537799A Pending JP2019506390A (ja) 2016-01-21 2017-01-18 合成オピオイドワクチン

Country Status (7)

Country Link
US (1) US11305010B2 (enExample)
EP (1) EP3405475B1 (enExample)
JP (1) JP2019506390A (enExample)
CN (1) CN108884127A (enExample)
BR (1) BR112018014908A2 (enExample)
RU (1) RU2018130106A (enExample)
WO (1) WO2017127390A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094528A1 (en) 2017-11-09 2019-05-16 The Scripps Research Institute An improved heroin vaccine
WO2020006563A1 (en) * 2018-06-29 2020-01-02 Marquette University Fluorinated compounds as ph-sensitive analgesics
WO2021092446A1 (en) * 2019-11-08 2021-05-14 Regents Of The University Of Minnesota Fentanyl hapten, fentanyl hapten-conjugates, and methods for making and using
US20230100186A1 (en) * 2020-01-13 2023-03-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Fentanyl haptens for the preparation of a fentanyl vaccine
WO2021183913A1 (en) * 2020-03-13 2021-09-16 Regents Of The University Of Minnesota Fentanyl haptens, fentanyl hapten conjugates, and methods for making and using
US20240307517A1 (en) * 2021-05-10 2024-09-19 Cornell University Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addiction
WO2024215826A2 (en) * 2023-04-13 2024-10-17 Avicenna Biotech Research, Llc Compositions and methods for treating fentanyl dependence

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
JPH07505634A (ja) 1992-04-06 1995-06-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド 新規オピエート誘導体，タンパクおよびポリペプチドオピエート誘導共役体および標識
US6262265B1 (en) 1999-06-18 2001-07-17 Microgenics Corporation Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
ES2284783T3 (es) * 2001-11-16 2007-11-16 Randox Laboratories Ltd. Metodo y estuche para detectar, o determinar la cantidad de,metabolitos de fentanilo y metabolitos de analogos de fentanilo.
KR101228376B1 (ko) * 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
WO2004111202A2 (en) * 2003-03-07 2004-12-23 Incyte Corporation Neurotransmission-association proteins
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
EP1850873B1 (en) * 2005-02-08 2018-11-28 Genzyme Corporation Antibodies to tgfbeta
US20110182918A1 (en) * 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
US9296802B2 (en) * 2009-04-15 2016-03-29 Postech Academy-Industry Foundation Target-specific non-antibody protein and method for preparing the same
CA2818548A1 (en) * 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
CA2857645A1 (en) * 2011-11-30 2013-06-06 Wellstat Diagnostics, Llc Assays, antibodies, immunogens and compositions related to 5-fu
US20150343054A1 (en) 2011-12-21 2015-12-03 Kim D. Janda Heroin Haptens, Immunoconjugates and Related Uses
US20140093525A1 (en) 2012-09-17 2014-04-03 Minneapolis Medical Research Foundation Compositions and methods of treating opioid addiction
WO2014124317A1 (en) 2013-02-08 2014-08-14 Regents Of The University Of Minnesota Analgesic conjugates
US9213029B2 (en) * 2013-06-25 2015-12-15 Samsung Electronics Co., Ltd. Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients

Similar Documents

Publication Publication Date Title
JP2019506390A5 (enExample)
RU2018130106A (ru) Вакцина против синтетических опиоидов
Sulczewski et al. Nanoparticle vaccines against viral infections
Rudra et al. Suppression of cocaine-evoked hyperactivity by self-adjuvanting and multivalent peptide nanofiber vaccines
JP2014513725A5 (enExample)
JP2014515406A5 (enExample)
JP6389559B2 (ja) 不活化全粒子ワクチンを含有するマイクロニードルアレイ製剤およびその投与方法
JP2013534248A5 (enExample)
JP2012017342A5 (enExample)
JP2006527762A5 (enExample)
JP2012522802A5 (enExample)
TWI578997B (zh) 用於預防或治療菸鹼成癮之共軛體
Lockner et al. A conjugate vaccine using enantiopure hapten imparts superior nicotine-binding capacity
Crouse et al. A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models
JP2019536761A5 (enExample)
Zhou et al. pH-sensitive and biodegradable Mn3 (PO4) 2· 3H2O nanoparticles as an adjuvant of protein-based bivalent COVID-19 vaccine to induce potent and broad-spectrum immunity
JP2018505882A5 (enExample)
ES2565578T3 (es) Vacunas contra el cáncer que contienen epítopos de antígeno oncofetal
EP3823620A4 (en) OPIOID HAPTENES, CONJUGATES, VACCINES AND METHODS OF GENERATING ANTIBODIES
CN103768595A (zh) 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗
Cossette et al. Intranasal subunit vaccination strategies employing nanomaterials and biomaterials
Jacob et al. Investigations of enantiopure nicotine haptens using an adjuvanting carrier in anti-nicotine vaccine development
CU23917B1 (es) Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína
AU2018283973A1 (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
RU2017103462A (ru) Материалы и способы, связанные с линкерами для применения в конъюгатах лекарственного средства и белка